Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432224 | 0.97 | SETD7 (0.40) | SETD7MAP4K4USP2SMN1; SMN2GPR119 | |
| SCHEMBL1197535 | 0.97 | SETD7 (0.40) | SETD7MAP4K4USP2SMN1; SMN2GPR119 | |
| SCHEMBL1197830 | 0.97 | SETD7 (0.40) | SETD7MAP4K4USP2SMN1; SMN2GPR119 | |
| SCHEMBL28315212 | 0.89 | SETD7 (0.35) | SETD7MAP4K4GPR119HSD17B10KDM4E | |
| SCHEMBL18198392 | 0.88 | HSD17B10 (0.41) | SETD7HSD17B10 | |
| SCHEMBL31080561 | 0.88 | HSD17B10 (0.41) | SETD7HSD17B10 | |
| SCHEMBL31080429 | 0.88 | HSD17B10 (0.41) | SETD7HSD17B10 | |
| SCHEMBL18198355 | 0.84 | SETD7 (0.39) | SETD7GPR119HSD17B10KDM4EMAPT | |
| SCHEMBL24267329 | 0.84 | SETD7 (0.38) | SETD7MAP4K4USP2SMN1; SMN2GPR119 | |
| SCHEMBL6745485 | 0.84 | SETD7 (0.38) | SETD7MAP4K4USP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | SETD7 1507/4885MAP4K4 1750/4885USP2 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.